283 related articles for article (PubMed ID: 25709357)
1. Macitentan: An important addition to the treatment of pulmonary arterial hypertension.
Khadka A; Singh Brashier DB; Tejus A; Sharma AK
J Pharmacol Pharmacother; 2015; 6(1):53-7. PubMed ID: 25709357
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
Sidharta PN; Krähenbühl S; Dingemanse J
Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):437-49. PubMed ID: 25604973
[TBL] [Abstract][Full Text] [Related]
3. The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension.
Steriade A; Seferian A; Jaïs X; Savale L; Jutant EM; Parent F; Sitbon O; Humbert M; Simonneau G; Montani D
Ther Adv Respir Dis; 2014 Jun; 8(3):84-92. PubMed ID: 24728960
[TBL] [Abstract][Full Text] [Related]
4. Dual ET
Nadeau V; Potus F; Boucherat O; Paradis R; Tremblay E; Iglarz M; Paulin R; Bonnet S; Provencher S
Pulm Circ; 2018; 8(1):2045893217741429. PubMed ID: 29064353
[TBL] [Abstract][Full Text] [Related]
5. A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.
Bedan M; Grimm D; Wehland M; Simonsen U; Infanger M; Krüger M
Basic Clin Pharmacol Toxicol; 2018 Aug; 123(2):103-113. PubMed ID: 29719121
[TBL] [Abstract][Full Text] [Related]
6. Endothelin research and the discovery of macitentan for the treatment of pulmonary arterial hypertension.
Clozel M
Am J Physiol Regul Integr Comp Physiol; 2016 Oct; 311(4):R721-R726. PubMed ID: 27534881
[TBL] [Abstract][Full Text] [Related]
7. Macitentan for the treatment of pulmonary arterial hypertension.
Hong IS; Coe HV; Catanzaro LM
Ann Pharmacother; 2014 Apr; 48(4):538-47. PubMed ID: 24458948
[TBL] [Abstract][Full Text] [Related]
8. Development of macitentan for the treatment of pulmonary arterial hypertension.
Selej M; Romero AJ; Channick RN; Clozel M
Ann N Y Acad Sci; 2015 Nov; 1358():68-81. PubMed ID: 26291180
[TBL] [Abstract][Full Text] [Related]
9. Macitentan: first global approval.
Patel T; McKeage K
Drugs; 2014 Jan; 74(1):127-33. PubMed ID: 24297706
[TBL] [Abstract][Full Text] [Related]
10. Macitentan (Opsumit) for the treatment of pulmonary arterial hypertension.
Clarke M; Walter C; Agarwal R; Kanwar M; Benza RL
Expert Rev Clin Pharmacol; 2014 Jul; 7(4):415-21. PubMed ID: 24851934
[TBL] [Abstract][Full Text] [Related]
11. [The new endothelin receptor antagonist macitentan: Prospects for therapy of pulmonary arterial hypertension].
Avdeev SN
Ter Arkh; 2016; 88(7):89-97. PubMed ID: 27459621
[TBL] [Abstract][Full Text] [Related]
12. Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience.
Belge C; Delcroix M
Ther Adv Respir Dis; 2019; 13():1753466618823440. PubMed ID: 30736726
[TBL] [Abstract][Full Text] [Related]
13. Macitentan in the treatment of pulmonary arterial hypertension.
Zebadúa R; Hernández-Pérez AP; García A; Zayas N; Sandoval J; López J; Pulido T
Future Cardiol; 2021 Jan; 17(1):49-58. PubMed ID: 32677463
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment of pulmonary arterial hypertension with macitentan in Japanese patients.
Tahara N; Dobashi H; Fukuda K; Funauchi M; Hatano M; Ikeda S; Joho S; Kihara Y; Kondo T; Matsushita M; Minamino T; Nakanishi N; Okano Y; Ozaki Y; Saji T; Sakai S; Tanabe N; Watanabe H; Yamada H; Yoshioka K; Hatta M; Sasayama S
Curr Med Res Opin; 2020 Jun; 36(6):921-928. PubMed ID: 32298185
[No Abstract] [Full Text] [Related]
15. New horizons for the use of the second generation of endothelin receptor antagonist macitentan in patients with pulmonary hypertension.
Martynyuk TV; Nakonechnikov SN; Chazova IY
Ter Arkh; 2018 Apr; 90(4):72-80. PubMed ID: 30701878
[TBL] [Abstract][Full Text] [Related]
16. Selective improvement of pulmonary arterial hypertension with a dual ET
Renshall L; Arnold N; West L; Braithwaite A; Pickworth J; Walker R; Alfaidi M; Chamberlain J; Casbolt H; Thompson AAR; Holt C; Iglarz M; Francis S; Lawrie A
Pulm Circ; 2018; 8(1):2045893217752328. PubMed ID: 29261014
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
Dingemanse J; Sidharta PN; Maddrey WC; Rubin LJ; Mickail H
Expert Opin Drug Saf; 2014 Mar; 13(3):391-405. PubMed ID: 24261583
[TBL] [Abstract][Full Text] [Related]
18. Novel dual endothelin receptor antagonist macitentan reverses severe pulmonary arterial hypertension in rats.
Kunita-Takanezawa M; Abe K; Hirooka Y; Kuwabara Y; Hirano K; Oka M; Sunagawa K
J Cardiovasc Pharmacol; 2014 Nov; 64(5):473-80. PubMed ID: 25084082
[TBL] [Abstract][Full Text] [Related]
19. Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial.
Jansa P; Pulido T
Am J Cardiovasc Drugs; 2018 Feb; 18(1):1-11. PubMed ID: 29280064
[TBL] [Abstract][Full Text] [Related]
20. Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis.
Raja SG
Curr Opin Investig Drugs; 2010 Sep; 11(9):1066-73. PubMed ID: 20730702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]